Language impairment in alzheimer's disease and benefits of acetylcholinesterase inhibitors

Steven H. Ferris, Martin Farlow

Research output: Contribution to journalReview article

41 Scopus citations

Abstract

Alzheimer's disease is characterized by progressively worsening deficits in several cognitive domains, including language. Language impairment in Alzheimer's disease primarily occurs because of decline in semantic and pragmatic levels of language processing. Given the centrality of language to cognitive function, a number of language-specific scales have been developed to assess language deficits throughout progression of the disease and to evaluate the effects of pharmacotherapy on language function. Trials of acetylcholinesterase inhibitors, used for the treatment of clinical symptoms of Alzheimer's disease, have generally focused on overall cognitive effects. However, in the current report, we review data indicating specific beneficial effects of acetylcholinesterase inhibitors on language abilities in patients with Alzheimer's disease, with a particular focus on outcomes among patients in the moderate and severe disease stages, during which communication is at risk and preservation is particularly important.

Original languageEnglish (US)
Pages (from-to)1007-1014
Number of pages8
JournalClinical interventions in aging
Volume8
DOIs
StatePublished - 2013

Keywords

  • Alzheimer's disease
  • Clinical trials
  • Cognition
  • Communication
  • Donepezil
  • Language

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Language impairment in alzheimer's disease and benefits of acetylcholinesterase inhibitors'. Together they form a unique fingerprint.

  • Cite this